Central nervous system tissue-labeling composition, method for labeling central nervous system tissue, and screening method using central nervous system tissue-labeling composition

A central nervous system tissue-labeling composition comprising, as an active ingredient, at least one compound represented by general formula (5):

• wherein R1 represents a hydrogen atom, an alkyl group, an aralkyl group, or an aryl group;
• R8 represents an alkyl group;
• X and Y represent a hydrogen atom or an alkyl group, or, alternatively, X and Y are bound together to form a ring;
• Z represents a hydrogen atom or a halogen atom;
• and n represents an integer of 0 or 1.

A method for labeling central nervous system tissue in a living body, comprising administering a central nervous system tissue-labeling composition comprising, as an active ingredient, at least one compound represented by general formula (5):

• wherein R1 represents a hydrogen atom, an alkyl group, an aralkyl group, or an aryl group;
• R8 represents an alkyl group;
• X and Y represent a hydrogen atom or an alkyl group, or, alternatively, X and Y are bound together to form a ring;
• Z represents a hydrogen atom or a halogen atom;
• and n represents an integer of 0 or 1.

A screening method for detecting a compound acting on a central nervous system tissue in vivo, the method comprising:

• administering a central nervous system tissue-labeling composition comprising, as an active ingredient, at least one compound represented by general formula (5):
• wherein R1 represents a hydrogen atom, an alkyl group, an aralkyl group, or an aryl group;
• R8 represents an alkyl group;
• X and Y represent a hydrogen atom or an alkyl group, or, alternatively, X and Y are bound together to form a ring;
• Z represents a hydrogen atom or a halogen atom;
• and n represents an integer of 0 or 1;
• and
• detecting in vivo the compound acting on the central nervous system tissue using the administered central nervous system tissue-labeling composition.